Partner with Lytix Biopharma
We are open to discussions on co-development and out-licensing opportunities for ruxotemitide in multiple oncology indications and LTX-401 globally.
Contact Business DevelopmentCurrent Partner
Verrica Pharmaceuticals
Nasdaq Listed
Ruxotemitide (LTX-315, VP-315)
Verrica Pharmaceuticals' license covers dermatological indications, including basal cell carcinoma and squamous cell carcinoma. Verrica has generated impressive Phase 2 data demonstrating a 51% complete response rate and clinical responses in 97% of patients with basal cell carcinoma.
Partnership Opportunities
We are actively seeking partners for co-development and outlicensing across key markets.
Asia/APAC Region
Seeking partners for ruxotemitide in the Asia/APAC region for neoadjuvant resectable melanoma and other oncology indications.
Co-Development
Open to co-development partnerships for expanding our pipeline into new indications and combination therapies.
LTX-401 Development
Partnership opportunities for LTX-401 development in deep-seated solid tumors including liver cancer.
A Platform Ready for Partnership
Lytix offers a unique opportunity to partner on first-in-class oncolytic molecule immunotherapies with strong Phase 2 data and clear regulatory pathways.
Ready to explore a partnership?
Contact our business development team to discuss co-development and outlicensing opportunities.